Clinical Trials Logo

Clinical Trial Summary

The proposed study consists of a multicentre prospective observational study involving patients with oligometastatic prostatic neoplasia defined according to CHAARTED criteria. The aim of the study is the creation of a registry including patients with newly diagnosed OMPCa, belonging to the main urological centres in the Triveneto region, in order to evaluate the oncological outcomes and the impact on the quality of life of local treatment of the primary neoplasm (surgical or radiotherapy) in addition to systemic hormonal treatment (ADT as monotherapy or in combination with Docetaxel/androgen receptor signal inhibitors (ARTA)). The above criteria define 'high metastatic volume' disease with the following parameters - ≥ 4 bone metastases, including at least one outside the spine and pelvis - Presence of visceral metastases Consequently, patients included in the study should not have the above-mentioned characteristics.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06273345
Study type Observational [Patient Registry]
Source Istituto Oncologico Veneto IRCCS
Contact Angelo Porreca, MD
Phone 0423 421321
Email angelo.porreca@iov.veneto.it
Status Recruiting
Phase
Start date January 23, 2023
Completion date January 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05496959 - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Phase 2
Withdrawn NCT04585932 - Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Phase 2
Not yet recruiting NCT05707468 - Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer N/A
Recruiting NCT06389786 - Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer N/A
Active, not recruiting NCT04190446 - Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment Phase 2
Recruiting NCT06205316 - SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Phase 3
Recruiting NCT05053152 - Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer Phase 2
Recruiting NCT06369610 - Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer Phase 2